Sugi Predict

Sugi Predict / Compounds / SCHEMBL17338792

SCHEMBL17338792

SCHEMBL17338792

CCOC(=O)C(=[N+]=[N-])c1ccc(Br)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.50
▸ MAPT P10636 3/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ S1PR4 O95977 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ S1PR1 P21453 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ ALDH1A1 P00352 3/20 0.43
▸ HPGD P15428 2/20 0.43
▸ NHERF1 O14745 1/20 0.42
▸ GSK3B P49841 1/20 0.41
▸ SIRT2 Q8IXJ6 1/20 0.40
▸ GAA P10253 2/20 0.40
▸ CES2 O00748 2/20 0.40
▸ CES1 P23141 2/20 0.40
▸ ACHE P22303 1/20 0.40
▸ FNTA P49354 1/20 0.40
▸ FNTB P49356 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28321122 0.87 SMN1; SMN2 (0.45) KMT2AMAPTMEN1LMNAALDH1A1
SCHEMBL29001221 0.85 CA1 (0.56) KMT2AMAPTMEN1LMNANPSR1
SCHEMBL28393255 0.84 KYAT1 (0.39) KMT2AMAPTMEN1LMNAALDH1A1
SCHEMBL28399426 0.84 MAPT (0.50) KMT2AMAPTMEN1LMNAMAPK1
SCHEMBL28783011 0.84 SMN1; SMN2 (0.49) KMT2AMAPTMEN1LMNANPSR1
SCHEMBL900466 0.83 ALDH1A1 (0.54) KMT2AMAPTMEN1LMNAALDH1A1
SCHEMBL14638705 0.83 KMT2A (0.40) KMT2AMAPTMEN1S1PR4LMNA
SCHEMBL28321032 0.83 HDAC3 (0.49) KMT2AMAPTALDH1A1GSK3BCES2
SCHEMBL1702960 0.81 MEN1 (0.44) KMT2AMAPTMEN1LMNAMAPK1
SCHEMBL22230717 0.81 MAPT (0.48) KMT2AMAPTMEN1S1PR4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651872-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS Septerna, Inc. (US) 2025-11-26 — — EP disclosed
CN-116514758-B Chromone derivative and synthesis method thereof 南京工业大学 2024-12-24 — — CN disclosed
WO-2024155601-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS SEPTERNA, INC. (US) 2024-07-25 — — WO disclosed
CN-116496160-B Construction method of meta carbon-carbon bond of phenolic compound 中国人民解放军陆军军医大学第二附属医院 2024-07-16 — — CN disclosed
CN-116514758-A Chromone derivative and synthesis method thereof 南京工业大学 2023-08-01 — — CN disclosed
CN-116496160-A Construction method of meta carbon-carbon bond of phenolic compound 中国人民解放军陆军军医大学第二附属医院 2023-07-28 — — CN disclosed
CN-114108011-B Synthesis method for constructing C-S or C-O bond in one step through electrochemistry 南京师范大学 2023-01-31 — — CN disclosed
US-20220315565-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FORMA THERAPEUTICS, INC. 2022-10-06 — — US disclosed
CN-113620824-B Method for realizing N-H insertion reaction of diazo acid ester compound and aniline molecule by utilizing photocatalytic microchannel 南京工业大学 2022-10-04 — — CN disclosed
CN-113683525-B Method for realizing N-H insertion reaction of ethyl phenyldiazoacetate and methylaniline by using micro-channel photoreaction technology 南京工业大学 2022-09-23 — — CN disclosed
US-10875848-B2 Inhibiting fatty acid synthase (FASN) FORMA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
CN-106470973-B Small molecule L FA-1 inhibitor 阿罗赛特制药公司 2020-08-04 — — CN disclosed
US-20200115368-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FORMA THERAPEUTICS, INC. 2020-04-16 — — US disclosed
EP-3636637-A1 INHIBITING FATTY ACID SYNTHASE (FASN) Forma Therapeutics, Inc. (US) 2020-04-15 — — EP disclosed
US-20190040008-A1 SMALL MOLECULE LFA-1 INHIBITORS ALLOCYTE PHARMACEUTICALS AG (CH) 2019-02-07 — — US disclosed
US-10077238-B2 Small molecule LFA-1 inhibitors ALLOCYTE PHARMACEUTICALS AG (CH) 2018-09-18 — — US disclosed
US-20170121284-A1 SMALL MOLECULE LFA-1 INHIBITORS ALLOCYTE PHARMACEUTICALS AG (CH) 2017-05-04 — — US disclosed
EP-3154941-A1 SMALL MOLECULE LFA-1 INHIBITORS AlloCyte Pharmaceuticals AG (CH) 2017-04-19 — — EP disclosed
WO-2015189265-A1 SMALL MOLECULE LFA-1 INHIBITORS ALLOCYTE PHARMACEUTICALS AG (CH) 2015-12-17 — — WO disclosed
CN-101503391-A 1,2-dihydroisoquinoline derivative and preparation thereof UNIV EAST CHINA NORMAL (CN) 2009-08-12 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10875848-B2 Inhibiting fatty acid synthase (FASN) FASN, SCD, FADS1 KMT2A 4377/4885MAPT 2981/4885MEN1 4802/4885
US-10077238-B2 Small molecule LFA-1 inhibitors ICAM1, VCAM1, ITGB1 KMT2A 1882/4885MAPT 4275/4885MEN1 3973/4885
US-20190040008-A1 SMALL MOLECULE LFA-1 INHIBITORS ICAM1, VCAM1, ITGB1 KMT2A 1882/4885MAPT 4275/4885MEN1 3973/4885
US-20170121284-A1 SMALL MOLECULE LFA-1 INHIBITORS ICAM1, VCAM1, ITGB1 KMT2A 1882/4885MAPT 4275/4885MEN1 3973/4885
US-20200115368-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FASN, SCD, FADS1 KMT2A 4377/4885MAPT 2981/4885MEN1 4802/4885
US-20220315565-A1 INHIBITING FATTY ACID SYNTHASE (FASN) FASN, SCD, FADS1 KMT2A 4377/4885MAPT 2981/4885MEN1 4802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.